Sector News

Sanofi to sell stake in Regeneron

May 26, 2020
Life sciences

Sanofi has revealed its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by the firm.

The French drugmaker currently holds around 23.2 million shares of Regeneron’s common stock, representing approximately 20.6% ownership, which it originally purchased in 2004.

Regeneron has agreed to repurchase $5 billion of its stock from Sanofi conditional on completion of the proposed public offering.

If the offering and repurchase are completed and the underwriters fully exercise their option to purchase additional shares, Sanofi will continue to own around 400,000 shares of Regeneron’s common stock, which it is retaining in support of the ongoing collaboration.

“Sanofi and Regeneron’s collaboration has been one of the most productive in the industry, creating significant value for both companies but more importantly, resulting in five important medicines for patients. Sanofi remains committed to continuing our collaboration with Regeneron which remains an integral part of our overall strategy, and this decision was fully aligned with Regeneron,” said Paul Hudson, Sanofi’s chief executive.

“The decision to divest our holdings is consistent with our efforts to enhance value creation for our shareholders. We believe the proceeds from this transaction will help further our ability to execute on our strategy to drive innovation and growth,” he added, further explaining the move.

The transaction has been approved by Sanofi and Regeneron’s Boards of Directors.

By: Selina McKee

Source: Pharma Times

Related News

October 17, 2020

Ong leaves Biogen to become CEO-partner at Flagship

Life sciences

LinkedIn Twitter Xing Facebook EmailThe appointment makes Tuyen Ong the latest in a series of new CEO-partners hired by Flagship. Flagship Pioneering has named Tuyen Ong as CEO-partner. The new […]

October 17, 2020

Pharma, take note: Millennials plan to spend more on meds, study says

Life sciences

LinkedIn Twitter Xing Facebook EmailThe COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, […]

October 17, 2020

AstraZeneca secures $486m from US for Covid-19 antibody

Life sciences

LinkedIn Twitter Xing Facebook EmailAstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment. AstraZeneca […]

Send this to a friend